Diabetes and hypertension increase the placental and transcellular permeation of the lipophilic drug diazepam in pregnant women

BMC Pregnancy and Childbirth

Momir Mikov⁶  Hani Al-Salami³  Svetlana Golocorbin-Kon⁴  Zorica Grujic⁵  Jovana Paunkovic²  Mladena Lalic-Popovic¹ 

[1] Department of Pharmacy, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia;Health department in Novi Sad for women health protection, Novi Sad, Serbia;Faculty of Health Science, Central Queensland University, Queensland, Australia;Faculty of Pharmacy, University of Montenegro, Podgorica, Montenegro;Clinic of Gynecology and Obstetric, Clinical Centre of Vojvodina, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia;Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University Novi Sad, Novi Sad, Serbia

关键词: Hypertension;    Diabetes;    Diazepam;    Drug placental-permeation;   

Others  :  1137847
DOI  :  10.1186/1471-2393-13-188

 received in 2013-05-17, accepted in 2013-09-30,  发布年份 2013

【 摘 要 】

Background

Previous studies carried out in our laboratories have demonstrated impaired drug permeation in diabetic animals. In this study the permeation of diazepam (after a single dose of 5 mg/day, administered intramuscularly) will be investigated in diabetic and hypertensive pregnant women.

Methods

A total 75 pregnant women were divided into three groups: group 1 (healthy control, n = 31), group 2 (diabetic, n = 14) and group 3 (hypertensive, n = 30). Two sets of diazepam plasma concentrations were collected and measured (after the administration of the same dose of diazepam), before, during and after delivery. The first set of blood samples was taken from the mother (maternal venous plasma). The second set of samples was taken from the fetus (fetal umbilical venous and arterial plasma). In order to assess the effect of diabetes and hypertension on diazepam placental-permeation, the ratios of fetal to maternal blood concentrations were determined. Differences were considered statistically significant if p ≤ 0.05.

Results

The diabetes and hypertension groups have 2-fold increase in the fetal umbilical-venous concentrations, compared to the maternal venous concentrations. Feto: maternal plasma-concentrations ratios were higher in diabetes (2.01 ± 1.10) and hypertension (2.26 ± 1.23) groups compared with control (1.30 ± 0.48) while, there was no difference in ratios between the diabetes and hypertension groups. Umbilical-cord arterial: venous ratios (within each group) were similar among all groups (control: 0.97 ± 0.32; hypertension: 1.08 ± 0.60 and diabetes: 1.02 ± 0.77).

Conclusions

On line with our previous findings which demonstrate disturbed transcellular trafficking of lipophilic drugs in diabetes, this study shows significant increase in diazepam placental-permeation in diabetic and hypertensive pregnant women suggesting poor transcellular control of drug permeation and flux, and bigger exposure of the fetus to drug-placental transport.

【 授权许可】

   
2013 Lalic-Popovic et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Al-Salami H, Butt G, Tucker I, Fawcett PJ, Golocorbin-Kon S, Mikov I, Mikov M: Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats. Eur J Drug Metab Pharmacokinet 2009, 34:43-50.
• [2]Silver RM: Implications of the first cesarean: perinatal and future reproductive health and subsequent cesareans, placentation issues, uterine rupture risk, morbidity, and mortality. Semin Perinatol 2012, 36:315-323.
• [3]Watson WJ, George RJ, Welter S, Day D: High-risk obstetric patients. Maternal morbidity after cesareans. J Reprod Med 1997, 42:267-270.
• [4]LoCicero AK: Explaining excessive rates of cesareans and other childbirth interventions: contributions from contemporary theories of gender and psychosocial development. Soc Sci Med 1993, 37:1261-1269.
• [5]Mandelli M, Tognoni G, Garattini S: Clinical pharmacokinetics of diazepam. Clin Pharmacokinet 1978, 3:72-91.
• [6]Bakke OM, Haram K: Time-course of transplacental passage of diazepam: Influence of injection-delivery interval on neonatal drug concentrations. Clin Pharmacokinet 1982, 7:353-362.
• [7]Combs CA, Gunderson E, Kitzmiller JL, Gavin LA, Main EK: Relationship of fetal macrosomia to maternal postprandial glucose control during pregnancy. Diabetes Care 1992, 15:1251-1257.
• [8]Mills JL: Malformations in infants of diabetic mothers. Teratology 1982, 25:385-394.
• [9]Reece EA, Eriksson UJ: The pathogenesis of diabetes-associated congenital malformations. Obstet Gynecol Clin North Am 1996, 23:29-45.
• [10]Misra DP, Salafia CM, Miller RK, Charles AK: Non-linear and gender-specific relationships among placental growth measures and the fetoplacental weight ratio. Placenta 2009, 30:1052-1057.
• [11]Myatt L: Role of placenta in preeclampsia. Endocrine 2002, 19:103-111.
• [12]Shafrir E, Khassis S: Maternal-fetal fat transport versus new fat synthesis in the pregnant diabetic rat. Diabetologia 1982, 22:111-117.
• [13]Thomas CR, Eriksson GL, Eriksson UJ: Effects of maternal diabetes on placental transfer of glucose in rats. Diabetes 1990, 39:276-282.
• [14]Many A, Schreiber L, Rosner S, Lessing JB, Eldor A, Kupferminc MJ: Pathologic features of the placenta in women with severe pregnancy complications and thrombophilia. Obstet Gynecol 2001, 98:1041-1044.
• [15]Salafia CM, Pezzullo JC, Lopez-Zeno JA, Simmens S, Minior VK, Vintzileos AM: Placental pathologic features of preterm preeclampsia. Am J Obstet Gynecol 1995, 173:1097-1105.
• [16]Ministry of Health of Republic Serbia: The good clinical practice national guidelines on diagnostic and treatment of arterial hypertension. In Book The Good Clinical Practice National Guidelines on Diagnostic and Treatment of Arterial Hypertension. Agency for the Accreditation of Health Care Institutions of Serbia; 2011:29-30.
• [17]Ministry of Health of Republic Serbia: The good clinical practice national guidelines on diabetes mellitus. In Book The Good Clinical Practice National Guidelines on Diabetes Mellitus. Agency for the Accreditation of Health Care Institutions of Serbia; 2012:69-71.
• [18]Rouini MR, Ardakani YH, Moghaddam KA, Solatani F: An improved HPLC method for rapid quantitation of diazepam and its major metabolites in human plasma. Talanta 2008, 75:671-676.
• [19]Jauniaux E, Jurkovic D, Lees C, Campbell S, Gulbis B: In-vivo study of diazepam transfer across the first trimester human placenta. Hum Reprod 1996, 11:889-892.
• [20]Dundee JW, Gamble JA, Assaf RA: Letter: plasma-diazepam levels following intramuscular injection by nurses and doctors. Lancet 1974, 2:1461.
• [21]Gamble JA, Dundee JW, Assaf RA: Plasma diazepam levels after single dose oral and intramuscular administration. Anaesthesia 1975, 30:164-169.
• [22]Lamson MJ, Sitki-Green D, Wannarka GL, Mesa M, Andrews P, Pellock J: Pharmacokinetics of diazepam administered intramuscularly by autoinjector versus rectal gel in healthy subjects: a phase I, randomized, open-label, single-dose, crossover, single-centre study. Clin Drug Invest 2011, 31:585-597.
• [23]Kanto J, Erkkola R, Sellman R: Accumulation of diazepam and N-demethyldiazepam in the fetal blood during the labour. Ann Clin Res 1973, 5:375-379.
• [24]Kanto J, Scheinin M: Placental and blood-CSF transfer of orally administered diazepam in the same person. Pharmacol Toxicol 1987, 61:72-74.
• [25]McCarthy GT, O'Connell B, Robinson AE: Blood levels of diazepam in infants of two mothers given large doses of diazepam during labour. J Obstet Gynaecol Br Commonwealth 1973, 80:349-352.
• [26]Haram K, Bakke OM: Diazepam as an induction agent for caesarean section: a clinical and pharmacokinetic study of fetal drug exposure. Br J Obstet Gynaecol 1980, 87:506-512.
• [27]Dagenais C, Rousselle C, Pollack GM, Scherrmann JM: Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice. J Cereb Blood Flow Metabol: Offic J Int Soc Cereb Blood Flow Metabol 2000, 20:381-386.
• [28]Park S, Sinko PJ: P-glycoprotein and mutlidrug resistance-associated proteins limit the brain uptake of saquinavir in mice. J Pharmacol Exp Therapeut 2005, 312:1249-1256.
• [29]Denson DD, Myers JA, Thompson GA, Coyle DE: The influence of diazepam on the serum protein binding of bupivacaine at normal and acidic pH. Anesth Analg 1984, 63:980-984.
• [30]Feldman SA, Crawley BE: Interaction of diazepam with the muscle-relaxant drugs. Br Med J 1970, 2:336-338.
• [31]Gerard JL, Edouard A, Berdeaux A, Duranteau J, Ahmad R: Interaction of intravenous diazepam and bupivacaine in conscious dogs. Reg Anesth 1989, 14:298-303.
• [32]Tomicheck RC, Rosow CE, Philbin DM, Moss J, Teplick RS, Schneider RC: Diazepam-fentanyl interaction–hemodynamic and hormonal effects in coronary artery surgery. Anesth Analg 1983, 62:881-884.
• [33]Schaira VR, Ranali J, Saad MJ, de Oliveira PC, Ambrosano GM, Volpato MC: Influence of diazepam on blood glucose levels in nondiabetic and non-insulin-dependent diabetic subjects under dental treatment with local anesthesia. Anesth Progr 2004, 51:14-18.
• [34]Chevassus H, Mourand I, Molinier N, Lacarelle B, Brun JF, Petit P: Assessment of single-dose benzodiazepines on insulin secretion, insulin sensitivity and glucose effectiveness in healthy volunteers: a double-blind, placebo-controlled, randomized cross-over trial [ISRCTN08745124]. BMC Clin Pharmacol 2004, 4:3.
• [35]al-Ahmed FA, el-Denshary ES, Zaki M, el-Sawaf HA, Abu-Jayyab AR: Interaction between diazepam and oral antidiabetic agents on serum glucose, insulin and chromium levels in rats. Biosci Rep 1989, 9:347-350.
• [36]Hill MD, Abramson FP: The significance of plasma protein binding on the fetal/maternal distribution of drugs at steady-state. Clin Pharmacokinet 1988, 14:156-170.
• [37]Kober A, Sjoholm I, Borga O, Odar-Cederlof I: Protein binding of diazepam and digitoxin in uremic and normal serum. Biochem Pharmacol 1979, 28:1037-1042.
• [38]Kuhnz W, Nau H: Differences in in vitro binding of diazepam and N-desmethyldiazepam to maternal and fetal plasma proteins at birth: relation to free fatty acid concentration and other parameters. Clin Pharmacol Therapeut 1983, 34:220-226.
• [39]Ridd MJ, Brown KF, Nation RL, Collier CB: The disposition and placental transfer of diazepam in cesarean section. Clin Pharmacol Therapeut 1989, 45:506-512.
• [40]Benet LZ, Hoener BA: Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Therapeut 2002, 71:115-121.
• [41]Berezhkovskiy LM: On the influence of protein binding on pharmacological activity of drugs. J Pharmaceut Sci 2010, 99:2153-2165.
• [42]Hammarlund-Udenaes M: Active-site concentrations of chemicals - are they a better predictor of effect than plasma/organ/tissue concentrations? Basic Clin Pharmacol Toxicol 2010, 106:215-220.
• [43]Schmidt S, Gonzalez D, Derendorf H: Significance of protein binding in pharmacokinetics and pharmacodynamics. J Pharmaceut Sci 2010, 99:1107-1122.
• [44]Anderson GJ, Miller JW: Benzodiazepines: chemistry, biotransformation, and pharmacokinetics. In Antiepileptic Drugs. 5th edition. Edited by Levy RH, Mattson RH, Meldrum BS, Perrucca E. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:187-205.
• [45]Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand 2008, 118:69-86.
• [46]Shand DG, Kornhauser DM, Wilkinson GR: Effects of route of administration and blood flow on hepatic drug elimination. J Pharmacol Exp Therapeut 1975, 195:424-432.
• [47]Syme MR, Paxton JW, Keelan JA: Drug transfer and metabolism by the human placenta. Clin Pharmacokinet 2004, 43:487-514.
• [48]Hakkola J, Raunio H, Purkunen R, Pelkonen O, Saarikoski S, Cresteil T, Pasanen M: Detection of cytochrome P450 gene expression in human placenta in first trimester of pregnancy. Biochem Pharmacol 1996, 52:379-383.
• [49]Pienimaki P, Lampela E, Hakkola J, Arvela P, Raunio H, Vahakangas K: Pharmacokinetics of oxcarbazepine and carbamazepine in human placenta. Epilepsia 1997, 38:309-316.
• [50]Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH, Chiba M, Lin JH: In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Therapeut 2001, 296:723-735.
• [51]Lima SA, Tavares J, Gameiro P, de Castro B, Cordeiro-da-Silva A: Flurazepam inhibits the P-glycoprotein transport function: an insight to revert multidrug-resistance phenotype. Eur J Pharmacol 2008, 581:30-36.
• [52]Resnick LM, Gupta RK, Sosa RE, Corbett ML, Laragh JH: Intracellular pH in human and experimental hypertension. Proc Natl Acad Sci USA 1987, 84:7663-7667.
• [53]Smallwood JI, Waisman DM, Lafreniere D, Rasmussen H: Evidence that the erythrocyte calcium pump catalyzes a Ca2+:nH + exchange. J Biol Chem 1983, 258:11092-11097.
• [54]Holcberg G, Tsadkin-Tamir M, Sapir O, Huleihel M, Mazor M, Ben Zvi Z: New aspects in placental drug transfer. Israel Med Assoc J: IMAJ 2003, 5:873-876.
• [55]Matthew Dawes PJC: Pharmacokinetics in pregnancy. Best Pract Res Clin Obstet Gynaecol 2001, 15:819-826.
• [56]van Geijn HP, Jongsma HW, Doesburg WH, Lemmens WA, de Haan J, Eskes TK: The effect of diazepam administration during pregnancy or labor on the heart rate variability of the newborn infant. Eur J Obstet Gynecol Reprod Biol 1980, 10:187-201.
• [57]Nau H, Luck W, Kuhnz W: Decreased serum protein binding of diazepam and its major metabolite in the neonate during the first postnatal week relate to increased free fatty acid levels. Br J Clin Pharmacol 1984, 17:92-98.